AMTD stock analysis

AMTD IDEA Group (AMTD) Shares of AMTD IDEA Group, one of the best value stocks, have been on the radar for months. The attention originates in the company’s tie-in with AMTD Digital Inc. Last year, HKD stock made a splash and brought a huge boost to small-caps thanks to its epic rally from around $12 to highs of over $2,550 in a few days. The Asian digital solution provider saw its shares explode as it made its public debut. The company’s parent AMTD Group was launched in 2003 by Hong Kong’s telco giant CK Hutchison, founded by billionaire Li Ka-shing. AMTD Digital was spun out in March. AMTD Idea Group is a subsidiary of AMTD Group Company Limited. According to AMTD Idea, it was expected to own 88.7% of the issued and outstanding shares and 99.4% of the total voting power in AMTD Digital following the IPO. Fast-forward to this year, and the two stocks continue moving in sympathy with one another. This week’s update from AMTD Digital’s AMTD Digital Media business is where stock market news comes to light. The company announced the successful completion of the shooting of the movie “My First of May,” which is also ready for market release. Following the update, shares of both AMTD and HKD stocks surged higher. Bright Green Corporation (BGXX) According to the short data from short interest api, shares of cannabis stocks haven’t been the best to watch over the last year. But sporadic trading action has made them some of the volatile stocks to watch daily. Bright Green’s plans to raise half a billion dollars under the government’s EB-5 capital program lit the initial fuse that sparked the rally in February. The company reported that it would leverage the program to help generate over 7,100 jobs in New Mexico and across the U.S. to support the construction of greenhouses and general operations. This week, Bright Green continued releasing updates. The company appointed its Chief Operating Officer, Seamus McAuley, to the CEO position. That news seems to have helped turn things around for BGXX stock after a week of trending lower. Vallon Pharmaceuticals, Inc. (VLON) In many cases, company news doesn’t have to be from a newswire alone. When it comes to public companies, filings come in handy. The fact that these are considered public disclosures means there doesn’t need to be a formal press release in conjunction with a filing. Vallon Pharmaceuticals is an example. This week, the company filed an amended S4 registration statement. In it, Vallon outlined its proposed merger with GRI Bio Inc. so that shareholders could be well-informed for the upcoming vote. Following its plan of searching for strategic alternatives in mid-2022, the company found an option in a merger with GRI. In December, Vallon, as one of the best growth stocks, detailed the plan for the tie-up, explaining that the focus will be on advancing GRI’s pipeline of NKT cell regulators for treating inflammatory, fibrotic, and autoimmune diseases. Since this deal is expected to close this quarter, speculation on its timing and, of course, the outcome of the shareholder vote has begun fueling market momentum for VLON stock.